CorePharm Bio wins patent dispute against ‘Astellas, a multinational pharma

Published: 2017-07-04 13:50:27

Updated: 2017-07-04 13:50:27

CorePharm Bio(CEO Jung-Tae Kim) announced that the Patent Court ruled the company’s A-Care Tab(generic name: solifenacin fumarate) does not infringe the Astellas’ solifenacin substance patent on the 30^th of June.

The Patent Court ruled “A patent whose term of existence is extended can be interpreted to affect pharmaceutical products that is a target of its product approval. A-Care Tab, a pharm...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.